HAEMATOLOGICA
Open Access
- 28 February 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (3), E103-+
- https://doi.org/10.3324/haematol.2017.182360
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematopoietic stem cell disorder which manifests with hemolysis (classical PNH) due to loss of expression of the CD55 and CD59 proteins, which leads to complement mediated cell lysis.[1][1] Despite being the only curative treatment for PNHKeywords
This publication has 14 references indexed in Scilit:
- Paroxysmal nocturnal hemoglobinuriaBlood, 2014
- Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuriaHaematologica, 2012
- Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuriaTurkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2011
- Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survivalBlood, 2011
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategoriesBlood, 2008
- Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006
- 1994 Consensus Conference on Acute GVHD Grading.1995